Meeting
2023 ASCO Genitourinary Cancers Symposium
Cascade genetic testing (CGT) female first-degree relatives (FDR) of men with germline BRCA2 mutations (gBRCA2mut) and prostate cancer (PCa): A cost-effectiveness analysis.
Authors
Alexie A Carletti
Oregon Health & Science University, Portland, OR
Alexie A Carletti , Aaron B Caughey , Alexandra Sokolova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 110)
DOI
10.1200/JCO.2023.41.6_suppl.110
Abstract #
110
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Impact of pre-surgical germline multigene panel testing on choice of surgery for breast cancer.
First Author: Elena Zarcaro
Poster
2014 Breast Cancer Symposium
Evaluation of the BRCA1 and BRCA2 mutation prediction models in Japanese patients with breast cancer.
First Author: Reiko Yoshida
Poster
2024 ASCO Annual Meeting
Genetic counseling and subsequent cascade genetic testing for women with a family history of pathogenic BRCA1 mutation: A cost-effectiveness model.
First Author: Allison Walker
Poster
2023 ASCO Annual Meeting
Women with pathogenic variants in moderate penetrance breast cancer genes: How frequently do they meet high penetrance genetic testing criteria?
First Author: Nicole Casasanta